The improved GH response to stimulation tests in obese subjects pretreated with acipimox has been suggesting elevated FFA levels to be involved in the mechanism behind the GH hyposecretion observed in obesity [28, 29]. This evidence concerns the gene GH1 and obesity due to melanocortin 4 receptor deficiency.